Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2020

View Archived Issues

Normal tissue gives clues to bladder cancer's beginnings

Tarsus announces data from phase II studies of TP-03 in Demodex blepharitis

MANF regulation seen to control hepatic lipid accumulation in NAFLD

Three's a crowd: Doudna-Charpentier duo is sole winner of chemistry Nobel

Gilead Sciences patents new HIV antivirals

Novartis discloses mTORC1 inhibitors

Korean researchers present EGFR inhibitors

NOD1 as a potential new therapeutic target for saturated-fat induced insulin resistance

Stanford University synthesizes new PI4K inhibitors

Responses seen with famitinib plus camrelizumab in ovarian and cervical cancer

Phase I data for CEND-1 plus gemcitabine and nab-paclitaxel in metastatic PDAC

Moleculin's WP-1096 and WP-1097 show in vitro activity for HIV, Zika and dengue fever

Primary endpoints not met with first-line durvalumab +/- tremelimumab in urothelial carcinoma

Study indicates potential of bosutinib to treat neurodegenerative conditions

mRNA-1273 vaccine candidate shows safety and immunogenicity in older adults

Toripalimab plus chemotherapy efficacious in treating advanced biliary tract cancer

Phase III study of Gamida Cell's omidubicel meets all secondary endpoints

IDMC recommends piclidenoson psoriasis study continue, rheumatoid arthritis trial end

New phase I study evaluates cord blood-derived NK cells preloaded with AFM-13

Napo initiates pivotal trial of crofelemer for cancer therapy-related diarrhea

Lilly reports interim data on combination therapy with LY-CoV555 and LY-CoV016 for COVID-19

Preclinical data support therapeutic potential of Molecular's anti-COVID-19 DARPin candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...